Recently on 10th February 2023, the European Medicines Agency (EMA) updated and released their "Validation checklist for Type II quality variations".
![](https://static.wixstatic.com/media/nsplsh_c5836f6a179e45d3bc92d12eb4ea433e~mv2.jpg/v1/fill/w_147,h_98,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_auto/nsplsh_c5836f6a179e45d3bc92d12eb4ea433e~mv2.jpg)
The EMA defines variation as a change to the terms of a marketing authorisation. A variation regulation governs the procedures for amending the marketing authorisation and technical dossier following the decision.
The following categories of variations are defined in Article 2 of the Variations Regulation:
Minor variations of Type IA
Minor variations of Type IB
Major variations of Type II
Extensions
Urgent safety restriction
According to Commission Regulation (EC) No 1234/2008 (the Variations Regulation), a major variation of type II is a variation that does not extend the marketing authorisation (line extension) but may significantly affect the safety, quality, or efficacy of a medicinal product.
The newly updated checklist will help to scrutinize the validation, click this LINK to see validation checkpoints for identifying type II variations.